Biomimetic cytomembrane nanovaccines prevent breast cancer development in the long term
Long Xiao(Nanjing University of Chinese Medicine), Yu Huang(Soochow University), Yuhe Yang(Hong Kong Polytechnic University), Zhiwei Miao(Nanjing University of Chinese Medicine), Jie Zhu(Nanjing University of Chinese Medicine), Mengdan Zhong(Nanjing University of Chinese Medicine), Chencheng Feng(Nanjing University of Chinese Medicine), Wenkai Tang(Nanjing University of Chinese Medicine), Jinhua Zhou(Soochow University), Lihong Wang(Nanjing University of Chinese Medicine), Xin Zhao(Hong Kong Polytechnic University), Zhirong Wang(Nanjing University of Chinese Medicine)
Cited by 41
Abstract
T cells and decreasing regulatory T cells in the tumor while increasing effector memory T cells in the spleen. Overall, our platform demonstrates that CCMP@R837 can be a potential candidate for preventive cancer vaccines in the clinic.
Related Papers
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Che‐Ming Jack Hu, Li Zhang, Santosh Aryal et al.|Proceedings of the National Academy of Sciences|2011|2.4k
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber, David H. Lawson, Jon Richards et al.|New England Journal of Medicine|2011|886